English to Russian Medical Medical: Pharmaceuticals

The median duration of therapy was 37 months (range: < 1 month to 50 months) in the cohort of 258 subjects with newly diagnosed chronic phase CML. In the pooled safety cohort of 2,182 subjects with CML or Ph+ ALL resistant or intolerant to imatinib, the median duration of exposure was 15 months (range 0 to 65.6 months). 5 A summarization of postmarketing safety information is also presented.